Clinical Characteristics and Response to Newer Quinolones in Legionella Pneumonia: A Report of 28 Cases

Journal of Chemotherapy

Volumn 15, Issue 5, 2003, Pages 461-465

  Santos, J ^a   Aguilar, L ^b   Garcia Mendez E ^b   Siquier, B ^c   Custardoy, J ^d   Garcia Rey C ^b   Pallares R ^e   Blanquer, R ^f   Caminero, J ^g   Dal Re R ^b   Duran J ^g   Gil Aguado, A ^h   Grau, I ⁱ   Ibanez D ^d   Llorca, E ^j   Martinez J ^k   Molinos, L ^k   Mensa, J ^l   Moreno, S ^m   Palacios, R ⁿ   Vidal, J ^o   more..

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^b GLAXOSMITHKLINE   (Spain)

^c HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^d HOSPITAL VEGA BAJA   (Spain)

^e HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^f H Dr Peset   (Spain)

^g HOSPITAL TXAGORRITXU   (Spain)

^h HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

ⁱ H Bellvitge   (Spain)

^j Hospital de Elda   (Spain)

^k HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^l H Clinic i Provincial   (Spain)

^m Universitario Morales Meseguer   (Spain)

ⁿ H Virgen de la Victoria   (Spain)

^o Son Dureta Children's Hospital   (Spain)

more..

Author keywords

Gemifloxacin; Legionella; Pneumonia; Therapy; Trovafloxacin

Indexed keywords

GEMIFLOXACIN; IMMUNOGLOBULIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TROVAFLOXACIN;

ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL PNEUMONIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; HUMAN; LEGIONELLA PNEUMOPHILA; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RASH;

EID: 10744227363     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2003.15.5.461     Document Type: Article

References (28)

1. Tsakris A, Alexiou-Daniel S, Souliou E, Antoniadis A. In-vitro activity of antibiotics against Legionella pneumophila isolates from water systems. J Antimicrob Chemother 1999; 44 (5): 693-5.
2. Edelstein PH. Antimicrobial chemotherapy for Legionnaires' disease: a review. Clin Infect Dis 1995; 21 Suppl 3: S265-76.
3. Edelstein PH, Edelstein MA, Ren J, Polzer R, Gladue RP. Activity of trovafloxacin (CP-99,219) against Legionella isolates: in vitro activity, intracellular accumulation and killing in macrophages, and pharmacokinetics and treatment of guinea pigs with L. pneumophila pneumonia. Antimicrob Agents Chemother 1996; 40 (2): 314-19.
4. Ruckdeschel G, Dalhoff A. The in-vitro activity of moxifloxacin against Legionella species and the effects of medium on susceptibility test results. J Antimicrob Chemother 1999; 43 Suppl B: 25-9.
5. Yu VL. Legionella pneumophila (Legionnaire' disease). In: Mandell GL, Bennett JE, Dolin R, editors. Principles and Practice of Infectious Diseases. 5th ed. New York: Churchill Livingstone; 2000: 2424-2435.
6. England AC, 3rd, Fraser DW, Plikaytis BD, Tsai TF, Storch G, Broome CV. Sporadic legionellosis in the United States: the first thousand cases. Ann Intern Med 1981; 94 (2): 164-70.
7. Plouffe JF. Importance of atypical pathogens of community-acquired pneumonia. Clin Infect Dis 2000; 31 Suppl 2: S35-9.
8. Lieberman D, Schlaeffer F, Boldur I, Horowitz S, Friedman MG, Leiononen M, et al. Multiple pathogens in adult patients admitted with community-acquired pneumonia: a one year prospective study of 346 consecutive patients. Thorax 1996; 51(2): 179-84.
9. Baquero F, Garcia-Rodriguez JA, Garcia de Lomas J, Aguilar L. Antimicrobial resistance of 1,113 Streptococcus pneumoniae isolates from patients with respiratory tract infections in Spain: results of a 1-year (1996-1997) multicenter surveillance study. The Spanish Surveillance Group for Respiratory Pathogens. Antimicrob Agents Chemother 1999; 43 (2): 357-9.
10. Chow AW, Hall CB, Klein JO, Kammer RB, Meyer RD, Remington JS, et al. In: Beam TR, Jr., Gilbert DN, Kunin CM, Party EW, editors. General guidelines for the evaluation of new antiinfective drugs for the treatment of respiratory tract infections: European Society of Clinical Microbiology and Infectious Diseases; 1993: 81-111.
11. Dedicoat M, Venkatesan P. The treatment of Legionnaires' disease. J Antimicrob Chemother 1999; 43(6): 747-52.
12. Bernander S, Gastrin B, Lofgren S, Olinder-Nielsen AM. Legionella urinary antigen in early disease. Scand J Infect Dis 1994; 26 (6): 777-8.
13. File TM, Jr., Segreti J, Dunbar L, Player R, Kohler R, Williams RR, et al. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrob Agents Chemother 1997; 41 (9): 1965-72.
14. Plouffe JF, Herbert MT, File TM, Jr., Baird I, Parsons JN, Kahn JB, et al. Ofloxacin versus standard therapy in treatment of community-acquired pneumonia requiring hospitalization. Pneumonia Study Group. Antimicrob Agents Chemother 1996; 40(5): 1175-9.
15. Monforte R, Estruch R, Vidal J, Mensa J, Marco F, Cervera R, et al. [A community outbreak of Legionnaires' disease in Barcelona: clinical and microbiological study]. Med Clin (Barc) 1989; 93(14): 521-5.
16. Lieberman D, Korsonsky I, Ben-Yaakov M, Lazarovich Z, Friedman MG, Dvoskin B, et al. A comparative study of the etiology of adult upper and lower respiratory tract infections in the community. Diagn Microbiol Infect Dis 2002; 42 (1): 21-8.
17. Lehtomaki K, Leinonen M, Takala A, Hovi T, Herva E, Koskela M. Etiological diagnosis of pneumonia in military conscripts by combined use of bacterial culture and serological methods. Eur J Clin Microbiol Infect Dis 1988; 7 (3): 348-54.
18. Lieberman D, Porath A, Schlaeffer F, Boldur I. Legionella species community-acquired pneumonia. A review of 56 hospitalized adult patients. Chest 1996; 109 (5): 1243-9.
19. Tan MJ, Tan JS, File TM, Jr. Legionnaires disease with bacteremic coinfection. Clin Infect Dis 2002; 35 (5): 533-9.
20. Maurin M, Raoult D. Q fever. Clin Microbiol Rev 1999; 12 (4): 518-53.
21. Finidori JP, Raoult D, Bornstein N, Fleurette J. Study of cross-reaction between Coxiella burnetii and Legionella pneumophila using indirect immunofluorescence assay and immunoblotting. Acta Virol 1992; 36 (5): 459-65.
22. Kohler RB, Winn WC, Jr., Wheat LJ. Onset and duration of urinary antigen excretion in Legionnaires disease. J Clin Microbiol 1984; 20 (4): 605-7.
23. Fields BS, Benson RF, Besser RE. Legionella and Legionnaires' disease: 25 years of investigation. Clin Microbiol Rev 2002; 15 (3): 506-26.
24. Dominguez JA, Manterola JM, Blavia R, Sopena N, Belda FJ, Padilla E, et al. Detection of Legionella pneumophila serogroup 1 antigen in nonconcentrated urine and urine concentrated by selective ultrafiltration. J Clin Microbiol 1996;34(9):2334-6.
25. Garcia MT, Pelaz C, Gimenez MJ, Aguilar L. In vitro activities of gemifloxacin versus five quinolones and two macrolides against 271 Spanish isolates of Legionella pneumophila: influence of charcoal on susceptibility test results. Antimicrob Agents Chemother 2000; 44(8): 2176-8.
26. Garcia I, Pascual A, Ballesta S, Joyanes P, Perea EJ. Intracellular penetration and activity of gemifloxacin in human polymorphonuclear leukocytes. Antimicrob Agents Chemother 2000; 44(11): 3193-5.
27. Garcia-de-Lomas J, Millas E, Lazaro MA, Bermejo M, Gimeno C, Navarro D, et al. A comparative study on the efficacy of the new quinolone alatrofloxacin in the treatment of experimental legionellosis in guinea pigs. Eur J Clin Microbiol Infect Dis 1998; 17(6): 420-3.
28. Edelstein PH, Shinzato T, Doyle E, Edelstein MA. In vitro activity of gemifloxacin (SB-265805, LB20304a) against Legionella pneumophila and its pharmacokinetics in guinea pigs with L. pneumophila pneumonia. Antimicrob Agents Chemother 2001; 45 (8): 2204-9.